Literature DB >> 16041023

In vitro cellular immune responses to recombinant antigens of Mycobacterium avium subsp. paratuberculosis.

Sung Jae Shin1, Chao-Fu Chang, Ching-Dong Chang, Sean P McDonough, Belinda Thompson, Han Sang Yoo, Yung-Fu Chang.   

Abstract

Five recombinant antigens (Ags; 85A, 85B, 85C, superoxide dismutase [SOD], and 35-kDa protein) were purified from Mycobacterium avium subsp. paratuberculosis and evaluated for their ability to stimulate peripheral blood mononuclear cells (PMBCs) from fecal-culture-positive cows (low and medium shedders) and culture-negative healthy cows. Recombinant Ags 85A, 85B, and 85C induced significant lymphocyte proliferation as well as the production of gamma interferon (IFN-gamma), interleukin-2 (IL-2), IL-12, and tumor necrosis factor alpha (TNF-alpha), but not IL-4, from low and medium shedders. The 85 antigen complex did not stimulate PMBC proliferation from culture-negative healthy cows. The 35-kDa protein also induced significant lymphocyte proliferation as well as the production of IFN-gamma and IL-4 from low and medium shedders. CD4(+) T cells and CD25(+) (IL-2R) T cells were stimulated the most by 85A and 85B, while the 35-kDa protein primarily stimulated CD21(+) B cells involved in humoral immune responses. Interestingly, SOD was less immunostimulatory than other antigens but strongly induced gammadelta(+) T cells, which are thought to be important in the early stages of infection, such as pathogen entry. These data provide important insight into how improved vaccines against mycobacterial infections might be constructed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041023      PMCID: PMC1201233          DOI: 10.1128/IAI.73.8.5074-5085.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  55 in total

1.  Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis.

Authors:  A M Caruso; N Serbina; E Klein; K Triebold; B R Bloom; J L Flynn
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

2.  The gammadelta T-cell bridge: linking innate and acquired immunity.

Authors:  T W Mak; D A Ferrick
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

3.  Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex.

Authors:  E Lozes; K Huygen; J Content; O Denis; D L Montgomery; A M Yawman; P Vandenbussche; J P Van Vooren; A Drowart; J B Ulmer; M A Liu
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

4.  Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis.

Authors:  A T Kamath; C G Feng; M Macdonald; H Briscoe; W J Britton
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

5.  A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection.

Authors:  E Jouanguy; S Lamhamedi-Cherradi; D Lammas; S E Dorman; M C Fondanèche; S Dupuis; R Döffinger; F Altare; J Girdlestone; J F Emile; H Ducoulombier; D Edgar; J Clarke; V A Oxelius; M Brai; V Novelli; K Heyne; A Fischer; S M Holland; D S Kumararatne; R D Schreiber; J L Casanova
Journal:  Nat Genet       Date:  1999-04       Impact factor: 38.330

6.  Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection.

Authors:  O Denis; A Tanghe; K Palfliet; F Jurion; T P van den Berg; A Vanonckelen; J Ooms; E Saman; J B Ulmer; J Content; K Huygen
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

7.  Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis.

Authors:  R N Coler; Y A Skeiky; T Vedvick; T Bement; P Ovendale; A Campos-Neto; M R Alderson; S G Reed
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

8.  Interferon-gamma and interleukin 4 gene expression in cows infected with Mycobacterium paratuberculosis.

Authors:  R W Sweeney; D E Jones; P Habecker; P Scott
Journal:  Am J Vet Res       Date:  1998-07       Impact factor: 1.156

9.  Early immunopathological events in experimental ovine paratuberculosis.

Authors:  I Begara-McGorum; L A Wildblood; C J Clarke; K M Connor; K Stevenson; C J McInnes; J M Sharp; D G Jones
Journal:  Vet Immunol Immunopathol       Date:  1998-05-29       Impact factor: 2.046

10.  Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors.

Authors:  A Tanghe; P Lefèvre; O Denis; S D'Souza; M Braibant; E Lozes; M Singh; D Montgomery; J Content; K Huygen
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

View more
  15 in total

1.  Mycobacteria Manipulate G-Protein-Coupled Receptors to Increase Mucosal Rac1 Expression in the Lungs.

Authors:  Nader Alaridah; Nataliya Lutay; Erik Tenland; Anna Rönnholm; Oskar Hallgren; Manoj Puthia; Gunilla Westergren-Thorsson; Gabriela Godaly
Journal:  J Innate Immun       Date:  2016-12-24       Impact factor: 7.349

2.  Mycobacterium paratuberculosis CobT activates dendritic cells via engagement of Toll-like receptor 4 resulting in Th1 cell expansion.

Authors:  Eui-Hong Byun; Woo Sik Kim; Jong-Seok Kim; Choul-Jae Won; Han-Gyu Choi; Hwa-Jung Kim; Sang-Nae Cho; Keehoon Lee; Tiejun Zhang; Gang Min Hur; Sung Jae Shin
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

3.  Cell-mediated and humoral immune responses after immunization of calves with a recombinant multiantigenic Mycobacterium avium subsp. paratuberculosis subunit vaccine at different ages.

Authors:  Aneesh Thakur; Claus Aagaard; Anders Stockmarr; Peter Andersen; Gregers Jungersen
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

4.  Divergent immune responses to Mycobacterium avium subsp. paratuberculosis infection correlate with kinome responses at the site of intestinal infection.

Authors:  Pekka Määttänen; Brett Trost; Erin Scruten; Andrew Potter; Anthony Kusalik; Philip Griebel; Scott Napper
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

5.  Antemortem and postmortem examinations of the cattle calf naturally infected with Mycobacterium avium subsp. paratuberculosis.

Authors:  Gangadhararao Appana; Dipankar Das; Maroudam Veerasami; Ramachandran Lakshmikanthan Senthilkumar; Munishkumar Durishetty; B Ramalakshmi; Vijay Bahekar; Falguni Mukherjee; Dev Chandran; P Uday Kumar; B Sesikeran; Villuppanoor Alwar Srinivasan
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2013-11-21

6.  Lymphoproliferative and gamma interferon responses to stress-regulated Mycobacterium avium subsp. paratuberculosis recombinant proteins.

Authors:  Ratna B Gurung; Douglas J Begg; Auriol C Purdie; Kumudika de Silva; John P Bannantine; Richard J Whittington
Journal:  Clin Vaccine Immunol       Date:  2014-04-02

7.  Phenotypic and transcriptomic response of auxotrophic Mycobacterium avium subsp. paratuberculosis leuD mutant under environmental stress.

Authors:  Jenn-Wei Chen; Joy Scaria; Yung-Fu Chang
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

8.  Description of a novel adhesin of Mycobacterium avium subsp. paratuberculosis.

Authors:  Mariana Noelia Viale; Gabriela Echeverria-Valencia; Pablo Romasanta; María Laura Mon; Marisa Fernandez; Emilio Malchiodi; María Isabel Romano; Andrea Karina Gioffré; María de la Paz Santangelo
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

Review 9.  Development of vaccines to Mycobacterium avium subsp. paratuberculosis infection.

Authors:  Hong-Tae Park; Han Sang Yoo
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

10.  A novel multi-antigen virally vectored vaccine against Mycobacterium avium subspecies paratuberculosis.

Authors:  Tim J Bull; Sarah C Gilbert; Saranya Sridhar; Richard Linedale; Nicola Dierkes; Karim Sidi-Boumedine; John Hermon-Taylor
Journal:  PLoS One       Date:  2007-11-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.